ARCA biopharma, Inc. (ABIO)


+0.07 (+3.48%)
Symbol ABIO
Price $2.08
Beta 1.463
Volume Avg. 0.03M
Market Cap 29.973M
Shares () -
52 Week Range 1.76-2.7
1y Target Est -
DCF Unlevered ABIO DCF ->
DCF Levered ABIO LDCF ->
ROE -22.39% Sell
ROA -23.04% Sell
Operating Margin -
Debt / Equity 3.39% Neutral
P/E -3.20 Strong Sell
P/B 0.72 Buy


Consensus EPS

Upgrades & Downgrades

Latest ABIO news

Dr. Michael R. Bristow M.D., Ph.D.
NASDAQ Capital Market

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.